Organ transplantation in the vasculitides

Current Opinion in Rheumatology

Volumn 15, Issue 1, 2003, Pages 22-28

  Schmitt, Wilhelm H ^a,b   Van der Woude, Fokko J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTROPHIL CYTOPLASMIC ANTIBODY;

GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SURVIVAL; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VASCULITIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CLINICAL TRIALS; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECURRENCE; VASCULITIS;

EID: 0037215625     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200301000-00005     Document Type: Review

References (57)

1. Allan A, Pusey C, Gaskin G: Outcome of renal replacement therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis. J Am Soc Nephrol 1998, 9:1258-1263. This retrospective, single-center analysis assessed the outcome of 59 AASV patients (both WG and MPA) during hemodialysis therapy and after renal transplantation (performed in 22 cases). In contrast to other case series, very low relapse rates were observed (0.09 and 0.02 per patient per year for patients on chronic dialysis and after transplantation, respectively), possibly due to prolonged immunosuppressive therapy, Relapse rates were not affected by ANCA positivity at the time of transplantation, duration of dialysis therapy, the nature of the AASV (WG or MPA), and the type of ANCA (proteinase 3 or myeloperoxidase).
2. Nachman PH, Segelmark M, Westaman K, et al.: Recurrent ANCA-associated small vessel vasculitis after transplantation: A pooled analysis. Kid Int 1999, 56:1544-1550. This retrospective analysis on the recurrence of AASV following renal transplantation pooled published case series of AASV patients who received a renal transplant with patients treated at the authors' institutions. Recurrence was observed in 17.3% of 127 cases. Treatment with cyclosporine A, circulating ANCAs at the time of transplantation, and diagnosis (WG or MPA) did not seem to influence relapse rate. Most relapses responded to the reinstitution of cyclophosphamide treatment.
3. Nissenson P, Port F: Outcome of end-stage renal disease in patients with rare courses of renal failure, III. Systemic/vascular disorders. Q J Med 1990, 74:63-74.
4. Weidemann S, Andrassy K, Ritz E: ANCA in haemodialysis patients. Nephrol Dial Transplant 1993, 8:839-845.
5. Oka K, Moriyama T, Izumi M, et al.: A case of relapse of cANCA-associated glomerulonephritis in post-transplant patients. Clin Transplant 2000, 14(suppl 3):33-36.
6. Ziff M, Jeldermann JH: Dialysis and transplantation in end-stage lupus nephritis. N Engl J Med 1983, 308:218-219.
7. Kuross S, Davin T, Kjellstrand CM: Wegener's granulomatosis with severe renal failure: Clinical course and results of dialysis and transplantation. Clin Nephrol 1981, 16:172-180
8. Haubitz M, Koch KM, Brunkhorst R: Survival and vasculitis activity in patients with end-stage renal disease due to Wegener's granulomatosis. Nephrol Dial Transplant 1998, 13:1713-1718. A detailed retrospective analysis of the clinical course of 35 patients with WG who developed end-stage renal failure, indicating sustained vasculitic activity despite renal failure (29 relapses in 17 patients; 0.24 relapses per patient per year). However, the survival of the patients was comparable to that of other patient groups with end-stage renal failure.
9. Schmitt WH, Haubitz M, Mistry N, et al.: Renal transplantation in Wegener's granulomatosis [letter]. Lancet 1993, 342:860. A brief retrospective report on 20 WG patients, demonstrating that relapse rates were lower after renal transplantation (0.1 relapse per patient per year) as compared with those before and during hemodialysis therapy (0.2 and 0.3 relapses per patient per year, respectively). Interestingly, six patients showed signs of active disease at the time of transplantation.
10. Jayne DRW: Conventional treatment and outcome of Wegener's granulomatosis and microscopic polyangiitis. Cleve Clin J Med 2002, 69(suppl 2):SII110-115. A summary of conventional forms of treatment for WG and MPA, including recent trials on cyclophosphamide (12-month course not better than 3 months, if remission achieved by 3 months) and methotrexate. The article explains the current strategy of stage-adapted treatment for WG and MPA.
11. De'Oliviera J, Gaskin G, Dash A, et al.: Relation between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 1995, 25:380-389.
12. Nowack R, Grab I, FIores-Suarez LF, et al.: ANCA titers, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA associated vasculitis. Nephrol Dial Transplant 2001, 16:1631-1637.
13. Mekhail TM, Hoffman GS: Longterm outcome of Wegener's granulomatosis in patients with renal disease requiring dialysis. J Rheumatol 2000, 27:1237-1240.
14. Franssen C, Gans R, Kallenberg C, et al.: Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: Distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies. J Intern Med 1998, 244:209-216. In a cohort of 46 patients tested positive for anti-PR3-ANCA and 46 patients tested positive for anti-MPO-ANCA, extra-renal disease manifestations, granuloma formation and relapses were significantly more prominent in anti-PR# ANCA than in anti-MPO-ANCA positive patients.
15. Reinhold-Keller E, Beuge N, Latza U, et al.: An interdisciplinary approach to the care of patients with Wegener's granulomatosis: Long-term outcome in 155 patients. Arhritis Rheum 2000, 43:1021-1032.
16. Brunner FP, Selwood NH: Profile of patients on RRT in Europe and death rates due to major causes of death groups. The EDTA Registration Committee. Kid Int (Suppl) 1992, 38:4-15.
17. Schnülle P, Lorenz D, Trede M, et al.: Impact of renal cadaveric transplantation on survival in end stage renal failure: Evidence for reduced mortality risk compared with hemodialysis during long-term follow up. J Am Soc Nephrol 1998, 9:2135-2142.
18. Wolfe RA, Ashby VB, Milford EL, et al.: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999, 341:1725-1730.
19. Schmitt WH, Opelz G, Van Der Woude FJ: Renal transplantation (RTx) is safe and successful in Wegener's granulomatosis (WG): Data from the Collaborative Transplant Study [abstract]. J Am Soc Nephrol 2002, 13:564A-565A.
20. Douglas Briggs J, Jones E: Registry report: Renal transplantation for uncommon diseases. Nephrol Dial Transplant 1999, 14:570-575.
21. Haubitz M, Kliem V, Koch KM, et al.: Renal transplantation for patients with autoimmune diseases: Single-center experience with 42 patients. Transplantation 1997, 15:1251-1257.
22. Rostaing L, Modesto A, Oksman F, et al.: Outcome of patients with antineutrophil cytoplasmic antibody-associated vasculitis following cadaveric kidney transplantation. Am J Kid Dis 1997, 29:96-102.
23. Wrenger E, Pirsch JD, Cangro CB, et al.: Single-center experience with renal transplantation in patients with Wegener's granulomatosis. Transplant Int 1997, 10:152-156.
24. Ramos EL: Recurrent diseases in the renal allograft. J Am Soc Nephrol 1991, 2:109-121.
25. Stegemann CA, Cohen-Tervaert JWC, De Jong PE, et al.: Trimethoprimsulfamethoxazole (Co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med 1996, 335:16-20.
26. Van Der Woude FJ: Kidney transplantation and ANCA associated vasculitis. Cleve Clin J Med 2002, 69(suppl 2):SII143-145. A recent summary of kidney transplantation in AASV, with a special emphasis on the impact of posttransplant immunosuppression on immunoregulation in AASV.
27. Noel L, Norin M, Thervet E, et al.: Successful kidney transplantation in a patient with microscopic polyarteritis and positive ANCA [abstract]. Clin Exp Immunol 1993, 93(suppl 1):43.
28. Frasca G, Neri L, Martello M, et al.: Renal transplantation in patients with microscopic polyarteritis anti-myeloperoxidase antibodies: Report of three cases. Nephron 1996, 27:82-85.
29. Nyberg G, Akesson P, Norden G, et. al.: Systemic vasculitis in a kidney transplant population. Transplantation 1997, 63:1273-1277.
30. Fauci A, Balow J, Brown R, et al.: Successful renal transplantation in Wegener's granulomatosis. Am J Med 1976, 60:437-440.
31. Fan SL, Lewis KE, Ball E, et al.: Recurrence of Wegener's granulomatosis 13 years after renal transplantation. Am J Kid Dis 2001, 38:E32.
32. Curtis J, Diethelm A, Herrera G, et al.: Recurrence of Wegener's granulomatosis in a cadaver renal allograft. Transplantation 1983, 36:452-454.
33. Grotz W, Wanner C, Rothere, et al.: Clinical course of patients with anti-neutrophil cytoplasm antibodies after kidney transplantation. Nephron 1995, 69:234-236.
34. Haubitz M, Olbricht CJ, Maschek H, et al.: Lethal relapse of Wegener's granulomatosis 4 years after successful kidney transplantation. Nephron 1995, 71:118-120.
35. Briganti EM, Russ GR, McNeil JJ, et al.: Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002, 347:103-109. A recent registry study from Australia demonstrating that allograft loss due to recurrent glomerulonephritis (observed in 2 of 102 patients) is rare in pauci-immune crescentic glomerulonephritis.
36. Boubenider S, Akhtar M, Atfurayh O, et al.: Late recurrence of Wegener's granulomatosis presenting as tracheal stenosis in a renal transplant patient. Clin Transplant 1994, 8:5-9.
37. Nachman PH, Hogan SL, Jennette JC, et al.: Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996, 7:33-39.
38. Westman KWA, Bygren PG, Olsson H, et al.: Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998, 9:842-852.
39. Schmitt WH, Heesen C, Csernok E, et al.: Elevated serum levels of soluble Interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. Arthritis Rheum 1992, 35:1088-1096.
40. Schmitt WH, Csernok E, Kobayashi S, et al.: Churg Strauss syndrome: Serum markers of lymphocyte activation and endothelial damage. Arhritis Rheum 1998, 41:445-452.
41. Stegemann CA, Cohen Tervaert JW, Huitema MG, et al.: Serum markers of T-cell activation in relapses of Wegener's granulomatosis. Clin Exp Immunol 1993, 91:415-420.
42. Schonermarck U, Csernok E, Trabandt A, et al.: Circulating cytokines and soluble CD23, CD26 and CD30 in ANCA-associated vasculitides. Clin Exp Rheumatol 2000, 18:457-63.
43. Nowack R, Göbel U, Klooker P, et al.: Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis-a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999;10: 1065-1071.
44. Reinhold-Keller E, Schmitt WH, Gross WL: Azathioprine toxicity mimicking a relapse of Wegener's granulomatosis. Rheumatology (Oxford) 2001, 40:831-832.
45. Maes B, Oellerich M, Ceuppens JL, et al.: A new inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis. Nephrol Dial Transplant 2002, 17:923-926. In two WG patients, the article describes an acute inflammatory syndrome, with fever, arthralgias, and muscle pain, that can mimic relapse of vasculitis and that seems to be induced by mycophenolic acid acyl glucuronide (positive rechallenge).
46. Contstantinescu AR, Liang M, Laskow DA: Sirolimus lowers myeloperoxidase and p-ANCA titers in a pediatric patient before kidney transplantation. Am J Kidney Dis 2002, 40:407-410.
47. Hagen EC, De Keizer RJ, Andrassy K, et al.: Compassionate treatment of Wegener's granulomatosis with rabbit anti-thymocyte globulin. Clin Nephrol 1995, 43:351-359.
48. Schmitt WH, Hagen EC, Van Der Woude FJ: T-cell directed treatment: Anti-thymocyte globulin. In Disease-Modifying Therapy in Vasculitides. Edited by Kallenberg CGM, Cohen-Tervaert JW. Basel: Birkhäuser Verlag; 2001:113-123.
49. Lockwood CM: Refractory Wegener's granulomatosis: A model for shorter immunotherapy of autoimmune diseases. J R Coll Physicians Lond 1998, 32:473-478.
50. Chow KM, Wang AY, Mac-Moune Lai F, et al.: Rapid recurrence of ANCA-negative pauci-immune vasculitis after cadaveric renal transplantation. Am J Kidney Dis 2001, 38:E3.
51. Kessler M, Hiesse C, Hestin D, et al.: Recurrence of immunoglobulin A nephropathy after renal transplantation in the cyclosporine era. Am J Kidney Dis 1996, 28:99-104.
52. Meulders Q, Pirson Y, Cosyns JP, et al.: Course of Henoch-Schonlein nephritis after renal transplantation: Report on ten patients and review of the literature. Transplantation 1994, 58:1179-1186.
53. Koutlas TC, Wernovsky G, Bridges ND, et al.: Orthotopic heart transplantation for Kawasaki disease after rupture if a giant coronary artery aneurysm. J Thorac Cardiovasc Surg 1997, 113:217-218.
54. Checchia PA, Pahl E, Shaddy RE, et al.: Cardiac transplantation for Kawasaki disease. Pediatrics 1997, 100:695-699.
55. Thomson D, Chamsi-Pasha H, Hasleton P: Heart transplantation for Churg-Strauss syndrome. Br Heart J 1989, 62:409-410.
56. Henderson RA, Hasleton P, Hamid BN: Recurrence of Churg-Strauss vasculitis in a transplanted heart. Br Head J 1993, 70:553.
57. Yeatman M, McNeil K, Smith JA, et al.: Lung transplantation in patients with systemic diseases: Eleven-year experience at Papworth Hospital. J Heart Lung Transplant 1996, 15:144-149.